



PEER-REVIEW REPORT

Name of journal: World Journal of Pharmacology

Manuscript NO: 41201

Title: Kv7 channels a potential therapeutic target in fibromyalgia: A hypothesis.

Reviewer's code: 00503486

Reviewer's country: United States

Science editor: Li-Jun Cui

Date sent for review: 2018-08-13

Date reviewed: 2018-08-13

Review time: 11 Hours

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input checked="" type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	(High priority)	<input checked="" type="checkbox"/> Anonymous
<input type="checkbox"/> Grade C: Good		<input type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of language polishing	(General priority)	Peer-reviewer's expertise on the topic of the manuscript:
<input type="checkbox"/> Grade E: Do not publish	<input type="checkbox"/> Grade D: Rejection	<input checked="" type="checkbox"/> Minor revision	<input checked="" type="checkbox"/> Advanced
		<input type="checkbox"/> Major revision	<input type="checkbox"/> General
		<input type="checkbox"/> Rejection	<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

The central sensitization hypothesis in fibromyalgia has so far led to inadequate therapy. The diagnosis of the disease depends on skin sensitivity to pain. Topical medicines may be of interest. The toxicities of retigabine and flupirtine make them bad choices for oral therapy.



**Baishideng
Publishing
Group**

7901 Stoneridge Drive, Suite 501,
Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

INITIAL REVIEW OF THE MANUSCRIPT

Google Search:

- The same title
- Duplicate publication
- Plagiarism
- No

BPG Search:

- The same title
- Duplicate publication
- Plagiarism
- No



PEER-REVIEW REPORT

Name of journal: World Journal of Pharmacology

Manuscript NO: 41201

Title: Kv7 channels a potential therapeutic target in fibromyalgia: A hypothesis.

Reviewer's code: 00504345

Reviewer's country: Bulgaria

Science editor: Li-Jun Cui

Date sent for review: 2018-08-13

Date reviewed: 2018-08-23

Review time: 9 Days

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language	(High priority)	<input checked="" type="checkbox"/> Anonymous
<input checked="" type="checkbox"/> Grade C: Good	polishing	<input checked="" type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of	(General priority)	Peer-reviewer's expertise on the
<input type="checkbox"/> Grade E: Do not	language polishing	<input type="checkbox"/> Minor revision	topic of the manuscript:
publish	<input type="checkbox"/> Grade D: Rejection	<input type="checkbox"/> Major revision	<input checked="" type="checkbox"/> Advanced
		<input type="checkbox"/> Rejection	<input type="checkbox"/> General
			<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

Dear colleague, It is good news for you to summarize in your new scientific review your long-standing scientific observations on such an important clinical issue as the treating of fibromyalgia. In the new review, you highlight several known facts about the pathogenesis of fibromyalgia namely the involvement of changes in the potassium



**Baishideng
Publishing
Group**

7901 Stoneridge Drive, Suite 501,
Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

channels in the development of clinical symptoms and the logical expectation the usage of well known Kv7 channel activators flupirtine and retigabine to be effective option in the healing practice. Still, the initial stages of clinical trials with both preparations do not provide satisfactory responses. I would allow myself to give you a possible answer to these preliminary clinical results. In your recent review in WJP (2017, 6 (1), 1-10) on table 2 you list a large number of drugs from different therapeutic groups used in treatment of fibromyalgia indicating that many factors are involved in its pathogenesis, not just changes in potassium channels. And we cannot expect that by applying flupirtine and retigabine, no matter how specific activators are on the potassium channels, we will achieve satisfactory results in their therapeutic application to treat fibromyalgia. Such a logical statement has found its place in the conclusion of your review

INITIAL REVIEW OF THE MANUSCRIPT

Google Search:

- The same title
- Duplicate publication
- Plagiarism
- No

BPG Search:

- The same title
- Duplicate publication
- Plagiarism
- No